Nicholas J. Vogelzang, MD of Comprehensive Cancer Centers of Nevada explains how he chooses the right prostate cancer patient for Zytiga (abiraterone acetate) or Xtandi (enzalutamide) at the 2017 Annual Meeting Annual Meeting in Chicago, IL.
How do you choose between or identify the right patient for Zytiga or Xtandi?
